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Background: Coexisting anxiety is common in major depressive disorder (MDD) and more difﬁcult to
treat than depression without anxiety. This analysis assessed the efﬁcacy, safety, and tolerability of
vortioxetine in MDD patients with high levels of anxiety (baseline Hamilton Anxiety Rating Scale [HAM-
A] total score Z20).
Methods: Efﬁcacy was assessed using an aggregated, study-level meta-analysis of 10 randomized, pla-
cebo-controlled, 6/8-week trials of vortioxetine 5–20 mg/day in adults (18–75 years), with a study in
elderly patients (Z65 years) analyzed separately. Outcome measures included mean differences from
placebo in change from baseline to endpoint (D) in the Montgomery-Åsberg Depression Rating Scale
(MADRS), HAM-A total, and HAM-A subscales. Safety and tolerability were assessed by treatment-
emergent adverse events (TEAEs).
Results: A total of 1497 (48.6%) vortioxetine-treated and 860 (49.1%) placebo-treated patients had
baseline HAM-AZ20. There were signiﬁcant differences from placebo in MADRS (vortioxetine 5 mg/day,
n¼415, D2.68, P¼0.005; 10 mg/day, n¼373, D3.59, Po0.001; 20 mg/day, n¼207, D4.30, P¼0.005)
and HAM-A total (5 mg/day, n¼419, D1.64, P¼0.022; 10 mg/day, n¼373, D2.04, P¼0.003; 20 mg/
day, n¼207, D2.19, P¼0.027). There were signiﬁcantly greater improvements versus placebo on the
HAM-A psychic subscale for all doses. The most common TEAEs (Z5.0%) were nausea, headache, diz-
ziness, dry mouth, diarrhea, nasopharyngitis, constipation, and vomiting. Incidence of serious TEAEs was
1.3% (placebo) and r1.3% (vortioxetine, across doses).
Limitations: Study heterogeneity limits this analysis. Patients with baseline HAM-AZ20 were not di-
rectly compared to baseline HAM-Ao20 or total MDD population.
Conclusions: Vortioxetine was efﬁcacious in reducing depressive and anxiety symptoms in patients with
MDD and high levels of anxiety.
Crown Copyright & 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).evier B.V. This is an open access a
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dwin).1. Introduction
Major depressive disorder (MDD) with prominent, coexisting
anxiety symptoms or with comorbid anxiety disorders is common,
disabling, and typically more difﬁcult to treat than MDD without
prominent anxiety. In population-based samples, 45–75% of MDD
patients are reported to have comorbid anxiety disorders (Kessler
et al., 2015; Schuch et al., 2014). Compared with patients who have
MDD without anxiety disorders, individuals affected by anxiety
and depressive symptoms concurrently have generally shown
greater functional disability, higher risk of suicidal ideation and
behavior (Hirschfeld, 2001; Sareen et al., 2005; Seo et al., 2011),
and increased utilization of health care resources (Hirschfeld,
2001; McLaughlin et al., 2006).
Antidepressants such as the SSRIs and SNRIs have efﬁcacy inrticle under the CC BY-NC-ND license
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treatments for patients with comorbid MDD and anxiety disorders
(Baldwin et al., 2014a; Saltiel and Silvershein, 2015). Clinical trials
have demonstrated that these agents are efﬁcacious in reducing
depressive symptoms versus placebo in patients with MDD and
high levels of anxiety symptoms (whether or not they meet the
criteria for anxiety disorders) without any single agent or class
showing a clear superiority (Altamura et al., 2004; Boulenger et al.,
2010; Fava et al., 2000; Maity et al., 2014; Rush et al., 2001; Thase
et al., 2014). However, considerable evidence suggests that high
levels of anxiety symptoms are predictive of poor response to
pharmacotherapies (Fava et al., 2008; Ionescu et al., 2014). For
example, in the STAR*D population, 53% of patients had ‘anxious
depression’ (deﬁned as a Hamilton Depression Rating Scale [HAM-
D] anxiety/somatization score Z7) (Hamilton, 1960) in addition to
MDD (Fava et al., 2008). Rates of response and remission were
signiﬁcantly lower in patients with anxious depression versus
non-anxious depression after citalopram monotherapy. Outcomes
continued to be worse in patients with anxious depression after
augmentation with or switching to bupropion, sertraline, or ven-
lafaxine. Patients with anxious depression experience more fre-
quent and more severe AEs compared with patients with non-
anxious depression (Fava et al., 2008). Furthermore, MDD patients
with anxiety symptoms who respond to treatment experience a
less durable response than do those without anxious depression
(Ionescu et al., 2014; Wiethoff et al., 2010). Based on this evidence,
more effective and long-lasting treatments are needed to reduce
the burden of illness in this patient population.
Vortioxetine is an antidepressant agent that is approved in the
US for the treatment of adults with MDD, and in the EU for the
treatment of MDEs in adults. Its mechanism of action is related to
its multimodal activity, which combines two pharmacological
properties: direct modulation of receptor activity and inhibition of
the 5-HT transporter. In addition to inhibiting the 5-HT transporter
(Bang-Andersen et al., 2011), vortioxetine is an antagonist at
5-HT3, 5-HT7, and 5-HT1D receptors, a partial agonist at 5-HT1B
receptors, and an agonist at 5-HT1A receptors (Bang-Andersen
et al., 2011; Mork et al., 2012; Westrich et al., 2012).
As of July 29, 2015, there have been 23 completed and reported
phase 2/3 clinical trials of vortioxetine in MDD, including 11 ran-
domized, double-blind, parallel-group, placebo-controlled studies
of 6/8 weeks’ duration that also included the Hamilton Anxiety
Rating Scale (HAM-A) total score (Hamilton, 1959) as a predeﬁned
efﬁcacy outcome measure (Alvarez et al., 2012; Baldwin et al.,
2012a; Boulenger et al., 2014; Henigsberg et al., 2012; Jacobsen
et al., 2015; Jain et al., 2013; Katona et al., 2012; Mahableshwarkar
et al., 2015a, 2013, 2015b; Takeda, 2013). In these MDD studies,
treatment with vortioxetine (in doses ranging from 5 to 20 mg/
day) was consistently associated with a dose related reduction in
anxiety symptoms in the overall MDD population. Clinical trials
evaluating the efﬁcacy of vortioxetine in the treatment of patients
with generalized anxiety disorder (GAD) with doses up to 10 mg/
day have yielded variable results (Baldwin et al., 2012b; Bidzan
et al., 2012; Mahableshwarkar et al., 2014a, 2014b; Rothschild
et al., 2012); though a recent independent meta-analysis of data
from 4 short-term, randomized controlled trials concluded that
vortioxetine has a favorable safety and efﬁcacy proﬁle in patients
with GAD (Pae et al., 2015).
The objectives of the present analyses were to evaluate the
efﬁcacy and safety of approved doses of vortioxetine (5–20 mg/
day) in the subgroup of MDD patients with high levels of anxiety
symptoms at baseline. High levels of anxiety symptoms were
predeﬁned in each individual study protocol as patients with
HAM-A total score Z20 at baseline. A HAM-A total score cutoff of
20 has been utilized in a number of clinical studies to distinguish
between anxious versus non-anxious MDD patients (Bandelowet al., 2014; Boulenger et al., 2010; Seo et al., 2011; Thase et al.,
2012). An additional efﬁcacy meta-analysis was also conducted in
the subgroup of MDD patients with more severe levels of anxiety
symptoms (HAM-A total score Z25 at baseline) (Kon-
stantakopoulos et al., 2013; Matza et al., 2010).2. Methods
2.1. Studies
The clinical development programme for vortioxetine in MDD
included 11 randomized, double-blind, placebo-controlled, multi-
centre, short-term (6 or 8 weeks' duration) studies that evaluated
vortioxetine (5–20 mg/day) in patients Z18 years old with MDD
and that documented baseline HAM-A scores (Supplemental Ta-
ble 1). Of these, 10 were included in the efﬁcacy meta-analyses
reported here. The remaining study—NCT00811252 (Katona et al.,
2012)—is analyzed separately because its study population dif-
fered by excluding individuals aged o65 years. For the pooled
safety analysis, all 11 trials were included.
All studies were designed and conducted in accordance with
the principles of the World Medical Association Declaration of
Helsinki, the International Conference on Harmonisation (ICH)
Harmonised Tripartite Guideline for Good Clinical Practice, and all
applicable local or regional regulatory requirements. The studies’
sponsors (Takeda Pharmaceutical Company, Ltd. and H. Lundbeck
A/S) assumed overall responsibility for the studies, including those
where monitoring was delegated to a contract research organi-
zation. Protocols, statistical analyses, and statistical reporting for
all studies were developed and conducted in compliance with
current scientiﬁc research approaches and relevant guidelines. The
details of the study designs and primary efﬁcacy results for all
included trials have been published (Alvarez et al., 2012; Baldwin
et al., 2012a; Boulenger et al., 2014; Henigsberg et al., 2012; Ja-
cobsen et al., 2015; Jain et al., 2013; Katona et al., 2012; Maha-
bleshwarkar et al., 2015a, 2013, 2015b; Takeda, 2013). Supple-
mental Table 1 provides a summary of treatment dosages, number
of patients in each dosage arm, treatment duration, and key MDD
inclusion criteria for all of the trials considered here.
For each of the 10 trials included in the efﬁcacy meta-analyses,
patients had to meet the criteria for an MDE (as described in the
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edi-
tion, Text Revision [DSM-IV-TR]) lasting at least 3 months and be
between 18 and 75 years of age (except NCT00839423 recruited
ages 18–65 years and NCT01255787 recruited ages 20–64 years).
Additional inclusion criteria included a Montgomery-Åsberg De-
pression Rating Scale (MADRS) (Montgomery and Asberg, 1979)
total score Z22 (NCT00672620 (Mahableshwarkar et al., 2013)),
Z30 (NCT00839423 (Alvarez et al., 2012) and NCT00672958 (Jain
et al., 2013)), or Z26 (all other studies). An additional eligibility
requirement of a Clinical Global Impressions–Severity of Illness
(CGI-S) (Guy, 1976) score Z4 was also required for NCT01140906
(Boulenger et al., 2014), NCT01153009 (Mahableshwarkar et al.,
2015b), NCT01163266 (Jacobsen et al., 2015), and NCT01179516
(Mahableshwarkar et al., 2015a). In study NCT00811252 (Katona
et al., 2012), patients were required to be aged Z65 years with a
MADRS total score Z26, as well as have current MDE duration of
Z4 weeks with Z1 MDE occurring before 60 years of age. Pa-
tients were excluded from these studies if they had any current
psychiatric disorder other than MDD (including anxiety disorders)
as deﬁned in the DSM-IV-TR.
2.2. Efﬁcacy
To investigate the efﬁcacy proﬁle of vortioxetine in the
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baseline, a primary, conservative meta-analysis (including all po-
sitive/supportive and failed/negative studies) was performed using
aggregated study-level data. A “positive” study was deﬁned as one
that demonstrates statistically signiﬁcant superiority on the pri-
mary efﬁcacy outcome versus either placebo, the current standard
(reference) treatment, or both; whereas a “supportive” study was
deﬁned as a study that may not demonstrate statistically sig-
niﬁcant superiority in the primary efﬁcacy outcome, but demon-
strates superiority on secondary efﬁcacy outcomes that are also
clinically relevant. Studies were considered as “failed” when both
the study drug and the reference treatment fail to demonstrate
statistically signiﬁcant superiority in efﬁcacy over placebo. “Ne-
gative” studies are those in which the study drug did not separate
from placebo but the reference treatment did.
For 7 of the 10 individual studies [i.e., excluding NCT00672958
(Jain et al., 2013), NCT00672620 (Mahableshwarkar et al., 2013),
and NCT00735709 (Henigsberg et al., 2012)], as well as for these
meta-analyses, the primary outcome measure was pre-deﬁned as
the change from baseline in MADRS total score at the end of the
treatment period. The primary endpoint for NCT00672958,
NCT00672620, and NCT00735709 was the change from baseline in
HAM-D 24-item total score, with change from baseline in MADRS
total score as a secondary outcome. In the present analyses, sec-
ondary endpoints included change from baseline in HAM-A total
score, HAM-A Item 1 (anxious mood), HAM-A somatic anxiety
subscale (combined Items 7–13 – somatic [muscular], somatic
[sensory], cardiovascular symptoms, respiratory symptoms, gas-
trointestinal symptoms, genitourinary symptoms, and autonomic
symptoms, respectively) (Hamilton, 1959), HAM-A psychic anxiety
subscale (combined items 1–6 plus Item 14 – anxious mood, ten-
sion, fears, insomnia, intellectual, depressed mood, and behavior
at interview, respectively) (Hamilton, 1959), MADRS Item 3 (inner
tension), CGI-S score, and Clinical Global Impressions–Improve-
ment (CGI-I) score.
A secondary meta-analysis was performed in the high anxiety
subgroup, which included only aggregated study-level data from
the 5 trials that did not enroll patients from the US (NCT00839423,
NCT00635219, NCT00735709, NCT01140906, and NCT01255787) to
evaluate issues of region and heterogeneity. Outcome measures
evaluated in this subgroup included the MADRS and HAM-A total
scores, HAM-A subscale scores, and CGI scores.
An additional meta-analysis was also conducted for the pri-
mary efﬁcacy outcome (MADRS total score) in patients with a
HAM-A total score Z25 at baseline to evaluate the depression
efﬁcacy of vortioxetine in the subgroup with the most severe an-
xiety symptoms. Results from the 10 adult trials were included in
this additional meta-analysis, with a secondary meta-analysis
limited to the 5 non-US trials in adults.
The effects of placebo and vortioxetine 5 mg/day treatments on
mean changes in MADRS scores and HAM-A scores were com-
pared for patients in the elderly study who had baseline HAM-A
total scores Z20.
2.3. Statistical analysis for efﬁcacy
An aggregated meta-analytic approach based on study-level
data was chosen as the statistical methodology as this method is
considered to provide the most reliable estimates of treatment
effect. Speciﬁcally, it efﬁciently and robustly handles heterogeneity
and the complexity arising from not having all dosages in all
studies.
All efﬁcacy meta-analyses were performed on the full analysis
set (FAS), deﬁned as all randomized patients who took at least
1 dose of the study medication and had at least 1 valid post-
baseline measurement of the primary efﬁcacy outcome (HAM-Atotal score for these analyses). The statistical methodologies used
in the individual studies formed the basis for the meta-analyses -
either a mixed-effect model for repeated measures (MMRM) or an
analysis of covariance (ANCOVA) using last observation carried
forward (LOCF) imputation. The MMRM was the primary efﬁcacy
analysis method used in 5 studies (NCT01179516, NCT00735709,
NCT01153009, NCT01163266, and NCT01140906) and an ANCOVA
(LOCF) was the primary in 5 studies (NCT00839423, NCT00635219,
NCT01255787, NCT00672958, and NCT00672620); however, all
included studies analyzed data by both MMRM and ANCOVA
(LOCF). The MMRM has speciﬁc attributes suited to the data
structure of acute-phase neuropsychiatric clinical studies and has
been compared extensively with the LOCF (Siddiqui et al., 2009).
Research indicates that, in many scenarios, analyses based on the
MMRM provide less biased estimates of treatment effect because
the assumption for the LOCF is often problematic in the real world
(Armitage and Colton, 1998; Siddiqui et al., 2009). In the current
meta-analysis, LOCF is utilized as a sensitivity analysis to the
MMRM. Standard methodology for MMRM and LOCF meta-ana-
lyses was applied (Armitage and Colton, 1998). Standardized effect
sizes were calculated as the Cohen's d statistic as mean and
standard deviation data were available for all studies. Results are
reported as the least squares (LS) mean difference from baseline
versus placebo (95% conﬁdence interval [CI]). All statistical tests
were two-sided with a 0.05 signiﬁcance level without multiplicity
adjustment.
2.4. Safety and tolerability
To determine the safety and tolerability proﬁle of vortioxetine
in MDD patients with high levels of anxiety symptoms, treatment-
emergent adverse events (TEAEs) were compiled separately for
placebo and each individual vortioxetine dose group using pooled
data from all 11 trials (includes efﬁcacy population plus the study
in elderly patients aged Z65 years (Katona et al., 2012)). The
safety set population comprised all randomized patients who re-
ceived at least 1 dose of the study medication. TEAEs were as-
sessed at each study visit (Weeks 1, 2, 4, 6, and 8) and evaluated
based on their frequency and whether they led to discontinuation.
In addition, listings of TEAEs were manually reviewed for potential
anxiogenic effects related to the initiation of vortioxetine, as
emergent anxiety has been reported in several studies of anti-
depressants after treatment initiation (Gollan et al., 2012; Grillon
et al., 2007; Li et al., 2011).3. Results
3.1. Patients
In the 10 adult studies included in the efﬁcacy meta-analysis,
1590 MDD patients were treated with placebo and 2856 with
therapeutic dosages of vortioxetine (Table 1a). At baseline, patients
in the overall MDD population had moderate-to-severe depres-
sion, as indicated by mean MADRS total score of E32 and mean
CGI-S score of E4.7, and had moderate anxiety, as indicated by
mean HAM-A total score of E20 (Busner et al., 2011; Matza et al.,
2010). A total of 771 (48.5%) patients in the placebo group and
1394 (48.8%) vortioxetine-treated patients had a baseline HAM-A
total score Z20 and were included in the primary subgroup meta-
analysis (Table 1b). Patients in this subgroup were slightly more
likely to be female, have a higher CGI-S score at baseline, and be
part of a non-US trial compared to patients in the overall MDD
population. Otherwise, the baseline characteristics in the 2 groups
were similar.
Table 1a
Summary of demographics, baseline characteristics, and baseline efﬁcacy para-
meters for the total MDD population included in the efﬁcacy meta-analysis of 10
short-term, placebo-controlled clinical studies of vortioxetine in patients with MDD
(full analysis set).
Placebo Vortioxetine
(N¼1590) 5 mg
(n¼989)
10 mg
(n¼835)
15 mg
(n¼436)
20 mg
(n¼596)
Age, years,
mean (SD)
43.8 (12.49) 44.1
(12.79)
44.8
(12.26)
44.9
(13.61)
44.2
(12.71)
Sex, female, n
(%)
1019 (64.1) 644 (65.1) 564 (67.5) 300 (68.8) 398 (66.8)
Race, n (%)
Caucasian 1268 (79.7) 752 (76.0) 631 (75.6) 360 (82.6) 457 (76.7)
Black 210 (13.2) 122 (12.3) 85 (10.2) 68 (15.6) 82 (13.8)
Asian 107 (6.7) 110 (11.1) 110 (13.2) 6 (1.4) 52 (8.7)
Othera 5 (0.3) 5 (0.5) 9 (1.1) 2 (0.5) 5 (0.8)
BMI, kg/m2
Mean (SD) 28.64 (7.12) 27.88
(7.34)
27.76
(6.85)
29.16
(7.18)
28.03
(6.94)
Duration of
current
MDE, n (%)
o24 weeks 724 (45.5) 494 (49.9) 436 (52.2) 194 (44.5) 248 (41.6)
Z24 weeks 866 (54.5) 495 (50.1) 395 (47.3) 242 (55.5) 348 (58.4)
Number of
previous
MDEs
Mean (SD) 2.7 (2.26) 2.8 (3.05) 2.7 (2.22) 2.7 (1.90) 2.7 (2.37)
Region, n (%)
US 892 (56.1) 445 (45.0) 297 (35.6) 287 (65.8) 295 (49.5)
Non-US 698 (43.9) 544 (55.0) 538 (64.4) 149 (34.2) 301 (50.5)
MADRS total
score
Mean (SD) 32.2 (4.02) 32.4
(4.04)
32.5
(4.07)
32.5
(4.09)
31.9 (3.99)
HAM-A total
score
Mean (SD) 19.7 (6.32) 20.1
(6.23)
20.6
(6.46)
19.4 (6.11) 18.9 (6.12)
Z20, n (%) 771 (48.5) 494 (49.9) 442 (52.9) 205 (47.0) 253 (42.4)
CGI-S total
score
Mean (SD) 4.7 (0.68) 4.8 (0.70) 4.7 (0.68) 4.7 (0.61) 4.6 (0.63)
CGI-S, Clinical Global Impressions–Severity of Illness; HAM-A, Hamilton Anxiety
Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; MDE, major
depressive episode; SD, standard deviation.
a Other: including American Indian/Alaska Native, Native Hawaiian (or other
Paciﬁc Islander), and missing.
Table 1b
Summary of demographics, baseline characteristics, and baseline efﬁcacy para-
meters for patients with baseline HAM-A total score Z20 included in the efﬁcacy
meta-analysis of 10 short-term, placebo-controlled clinical studies of vortioxetine
in patients with MDD (full analysis set).
Placebo Vortioxetine
(N¼771) 5 mg
(n¼494)
10 mg
(n¼442)
15 mg
(n¼205)
20 mg
(n¼253)
Age, years,
mean (SD)
44.7 (11.93) 43.8
(12.65)
44.8
(12.48)
44.2
(13.65)
45.4
(12.78)
Sex, female, n
(%)
545 (70.7) 351 (71.1) 308 (69.7) 149 (72.7) 185 (73.1)
Race, n (%)
Caucasian 641 (83.1) 385 (77.9) 343 (77.6) 177 (86.3) 210 (83.0)
Black 76 (9.9) 50 (10.1) 37 (8.4) 27 (13.3) 29 (11.5)
Asian 50 (6.5) 56 (11.3) 59 (13.3) 1 (0.5) 11 (4.3)
Othera 4 (0.5) 3 (0.6) 3 (0.7) 0 2 (1.2)
BMI, kg/m2
Mean (SD) 28.65 (7.20) 27.76
(7.40)
27.40
(6.49)
28.51
(6.95)
28.01
(6.94)
Duration of
current
MDE, n (%)
o24 weeks 360 (46.7) 249 (50.4) 233 (52.7) 98 (47.8) 106 (41.9)
Z24 weeks 411 (53.3) 245 (49.6) 206 (46.6) 107 (52.2) 147 (58.1)
Number of
previous
MDEs
Mean (SD) 2.7 (2.23) 2.6 (2.64) 2.5 (2.02) 2.6 (1.77) 2.8 (2.44)
Region, n (%)
US 376 (48.8) 204 (41.3) 129 (29.2) 118 (57.6) 114 (45.1)
Non-US 395 (51.2) 290 (58.7) 313 (70.8) 87 (42.4) 139 (54.9)
MADRS total
score
Mean (SD) 33.3 (4.04) 33.3
(4.23)
33.3 (4.15) 33.7
(4.23)
33.1 (4.04)
HAM-A total
score
Mean (SD) 24.9 (4.21) 25.1
(4.27)
25.4
(4.59)
24.6
(4.29)
24.6 (4.25)
Z20, n (%) 771 (100.0) 494
(100.0)
442
(100.0)
205
(100.0)
253
(100.0)
CGI-S total
score
Mean (SD) 4.9 (0.66) 4.9 (0.68) 4.9 (0.66) 4.7 (0.60) 4.8 (0.64)
CGI-S, Clinical Global Impressions–Severity of Illness; HAM-A, Hamilton Anxiety
Rating Scale; MADRS, Montgomery-Åsberg Depression Rating Scale; MDE, major
depressive episode; SD, standard deviation.
a Other: including American Indian/Alaska Native, Native Hawaiian (or other
Paciﬁc Islander), and missing.
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3.2.1. MADRS total score
The difference from placebo in MADRS total score for the change
from baseline to Week 6/8 in patients with baseline HAM-A total
score Z20 was statistically signiﬁcantly in favor of vortioxetine
5 mg/day (P¼0.005), 10 mg/day (Po0.001), and 20 mg/day
(P¼0.005), but not vortioxetine 15 mg/day (P¼0.650) (Fig. 1). In-
spection of standardized effect size (SES) scores in studies analyzing
41 vortioxetine dose suggests a dose-related trend in clinical re-
sponse, with larger effects being experienced at higher doses.
When restricting the meta-analysis to MDD patients with a
baseline HAM-A total score Z20 in the 5 studies conducted out-
side of the US, the results were statistically signiﬁcantly in favor of
vortioxetine 5 mg/day (P¼0.025), 10 mg/day (Po0.001), and
15 mg/day (Po0.001), with near-signiﬁcance for vortioxetine
20 mg/day (P¼0.051) (Fig. 1).
In the elderly study (NCT00811252) (Katona et al., 2012),treatment with vortioxetine 5 mg/day in those who had baseline
HAM-A total score Z20 resulted in a statistically signiﬁcant LS
mean difference from placebo in change from baseline in MADRS
total score.
In the additional analysis of MDD patients with more severe
anxiety symptoms (HAM-A total score Z25) at baseline, vortiox-
etine 5 mg/day and 10 mg/day demonstrated a signiﬁcantly
greater change from baseline versus placebo in MADRS total score
(P¼0.049 and Po0.001, respectively), while vortioxetine 15 mg/
day and 20 mg/day failed to separate (P¼0.535 and P¼0.090, re-
spectively) (Supplemental Fig. 1). When limiting to studies con-
ducted outside the US, vortioxetine 5 mg/day and 10 mg/day kept
their statistical signiﬁcance versus placebo (P¼0.008 and
Po0.001, respectively) and vortioxetine 20 mg/day reached sta-
tistical signiﬁcance (P¼0.030), whereas vortioxetine 15 mg/day
failed to separate from placebo (P¼0.102).
Fig. 1. Difference from placebo in MADRS total score change from baseline at Week 6/8: Baseline HAM-A Z20 population (FAS, MMRM). Studies included in the non-US
analysis: NCT00839423, NCT00635219, NCT00735709, NCT01140906, and NCT01255787. CI, conﬁdence interval; SES, standardized effect size; VOR, vortioxetine.
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In the subgroup of MDD patients with high levels of anxiety
symptoms (baseline HAM-A total score Z20), statistically sig-
niﬁcant differences from placebo in HAM-A total score were de-
monstrated by vortioxetine 5 mg/day (P¼0.022), 10 mg/day
(P¼0.003), and 20 mg/day (P¼0.027) at study endpoint, but not
for vortioxetine 15 mg/day (P¼0.886) (Fig. 2A). In the meta-ana-
lysis of studies conducted outside of the US, vortioxetine 5, 10, and
15 mg/day displayed statistically signiﬁcant mean differences from
placebo at study endpoint (P¼0.030, P¼0.002, and P¼0.047, re-
spectively), while vortioxetine 20 mg/day was close to reaching
statistical signiﬁcance (P¼0.053) (Fig. 2A). In MDD patients with a
baseline HAM-A total score Z20 who were treated with vortiox-
etine 5 mg/day in the dedicated elderly study (NCT00811252), the
mean difference from placebo in change from baseline HAM-A
total score was statistically signiﬁcant in favor of vortioxetine
(P¼0.001).
The results from the total MDD population included in this
meta-analysis were similar to that of the MDD population with
high levels of anxiety symptoms, including the dose-response re-
lationship of vortioxetine 5, 10, and 20 mg/day (Fig. 2B). These
results are also similar to the results of the total MDD population
enrolled in the non-US studies, including the dose-response
relationship.
The LS mean difference from placebo in HAM-A total score
change from baseline was additionally assessed by study visit for
the MDD population with high levels of anxiety symptoms and theoverall MDD population from the 8-week trials. In the subgroup
with high levels of anxiety, the difference from placebo was sta-
tistically signiﬁcant from the second on-treatment study visit
(Week 4) for vortioxetine 10 mg/day, and remained signiﬁcantly
different through Week 8 (Fig. 3A). In the overall MDD population,
the difference from placebo was statistically signiﬁcant beginning
at Week 2 for vortioxetine 10 mg/day and at Week 4 for vortiox-
etine 20 mg/day, and remained signiﬁcant through Week 6 and
Week 8, respectively (Fig. 3B).
3.2.3. HAM-A subscale scores
In the evaluation of HAM-A subscales, analysis was based on
HAM-A Item 1 (anxious mood), somatic anxiety subscale, and
psychic anxiety subscale (Fig. 4). In change from baseline on HAM-
A Item 1, the meta-analysis of both the total MDD population and
the MDD subgroup with high-level anxiety symptoms yielded
statistically signiﬁcant results versus placebo for vortioxetine
5 mg/day (total, P¼0.009; high anxiety, P¼0.044) and 10 mg/day
(total, Po0.001; high anxiety, P¼0.003), but not for vortioxetine
15 mg/day (total, P¼0.331; high anxiety, P¼0.708) or 20 mg/day
(total, P¼0.162; high anxiety, P¼0.135).
On the somatic anxiety subscale, neither population yielded
signiﬁcant results for any of the vortioxetine doses. In contrast, on
the psychic anxiety subscale there were statistically signiﬁcant
differences from placebo in change from baseline in both meta-
analysis populations for the vortioxetine 5 mg/day (total,
P¼0.008; high anxiety, P¼0.007), 10 mg/day (total, Po0.001;
Fig. 2. A. Difference from placebo in HAM-A total score change from baseline at Week 6/8: Baseline HAM-A Z20 population (FAS, MMRM). Studies included in the non-US
analysis: NCT00839423, NCT00635219, NCT00735709, NCT01140906, and NCT01255787. CI, conﬁdence interval; SES, standardized effect size; VOR, vortioxetine. B. Difference
from placebo in HAM-A total score change from baseline at Week 6/8: Total MDD population (FAS, MMRM). Studies included in the non-US analysis: NCT00839423,
NCT00635219, NCT00735709, NCT01140906, and NCT01255787. CI, conﬁdence interval; SES, standardized effect size; VOR, vortioxetine.
Fig. 3. A. Difference from placebo in HAM-A total score change from baseline by study visit in the 8-week studies: Baseline HAM-A Z20 population (FAS, MMRM). Studies
included in the 8-week analysis: NCT00635219, NCT00735709, NCT01140906, NCT01153009, NCT01163266, NCT00672620, and NCT01179516. NCT01255787 was not in-
cluded because the HAM-A was only assessed at baseline and at Weeks 4 and 8. *Po0.05,**Po0.01 versus placebo. VOR, vortioxetine. B. Difference from placebo in HAM-A
total score change from baseline by study visit in the 8-week studies: Total MDD population (FAS, MMRM). Studies included in the 8-week analysis: NCT00635219,
NCT00735709, NCT01140906, NCT01153009, NCT01163266, NCT00672620, and NCT01179516. NCT01255787 was not included because the HAM-A was only assessed at
baseline and at Weeks 4 and 8. *Po0.05,**Po0.01,***Po0.001 vs placebo. VOR, vortioxetine.
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high anxiety, Po0.001), but not for vortioxetine 15 mg/day (total,
P¼0.108; high anxiety, P¼0.329). The psychic anxiety subscale
results provide some evidence for a dose-response relationship
(not including vortioxetine 15 mg/day) as seen with the SES
(Fig. 4).
In the elderly study, which only assessed vortioxetine 5 mg/day,
patients with MDD and high levels of anxiety symptoms demon-
strated a statistically signiﬁcant improvement in both the somatic
and psychic anxiety subscales (P¼0.008 and P¼0.001, respec-
tively). This signiﬁcance was also attained in the total MDD po-
pulation for this study in both HAM-A subscales (P¼0.015 and
Po0.001, respectively) (Fig. 4).3.2.4. MADRS Item 3 (‘Inner Tension’) analysis
Analysis of the difference from placebo in the change from
baseline to study endpoint in inner tension for patients with
baseline HAM-A total score Z20 demonstrated a consistent dose
effect in favor of vortioxetine through the range of approved doses
(5 mg/day, n¼415, D0.28 [0.52,0.04], P¼0.025; 10 mg/day,
n¼373, D0.37 [0.53,0.21], Po0.001; 15 mg/day, n¼171,
D0.10 [0.83, 0.63], P¼0.783; 20 mg/day, n¼207, D0.39
[0.65,0.14], P¼0.003).
3.2.5. CGI scores
The meta-analyses of CGI-I and CGI-S scores supported the
results of overall analysis of the MADRS and HAM-A total scores.
The meta-analysis of difference from placebo in CGI-I score change
Fig. 4. Difference from placebo in HAM-A subscale scores change from baseline at Week 6/8: (A) total MDD population and (B) baseline HAM-A Z20 population (FAS,
MMRM). The psychic anxiety subscale score is the sum of HAM-A items 1, 2, 3, 4, 5, and 6. The somatic anxiety subscale score is the sum of HAM-A Items 7, 8, 9, 10, 11, 12, 13,
and 14. CI, conﬁdence interval; SES, standardized effect size.
Fig. 5. Difference from placebo in CGI-I total score change from baseline at Week 6/8: Baseline HAM-A Z20 population (FAS, MMRM). Studies included in the non-US
analysis: NCT00839423, NCT00635219, NCT00735709, NCT01140906, and NCT01255787. CI, conﬁdence interval; SES, standardized effect size; VOR, vortioxetine.
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Table 2
Summary of adverse events at the end of the study period for patients with
baseline HAM-A total score Z20 included in the safety meta-analysis of 11 short-
term, placebo-controlled clinical studies of vortioxetine in patients with MDD
(safety set).
Placebo Vortioxetine
(N¼860) 5 mg
(n¼583)
10 mg
(n¼448)
15 mg
(n¼210)
20 mg
(n¼256)
Treatment-emergent adverse events (TEAEs), n (%)
Any TEAE 547 (63.6) 394
(67.6)
295
(65.8)
158
(75.2)
182 (71.1)
TEAEs leading to
discontinuation
38 (4.4) 29 (5.0) 31 (6.9) 13 (6.2) 22 (8.6)
Serious TEAEs 11 (1.3) 6 (1.0) 6 (1.3) 1 (0.5) 3 (1.2)
Serious TEAEs lead-
ing to
discontinuation
4 (0.5) 4 (0.7) 5 (1.1) 0 1 (0.4)
TEAEs with incidence of Z5% in any treatment arm, n (%)
Nausea 81 (9.4) 131
(22.5)
118
(26.3)
65 (31.0) 72 (28.1)
Headache 137 (15.9) 85 (14.6) 69 (15.4) 35 (16.7) 32 (12.5)
Dizziness 53 (6.2) 36 (6.2) 28 (6.3) 16 (7.6) 25 (9.8)
Dry mouth 59 (6.9) 40 (6.9) 27 (6.0) 16 (7.6) 21 (8.2)
Diarrhea 46 (5.3) 31 (5.3) 30 (6.7) 24 (11.4) 12 (4.7)
Nasopharyngitis 37 (4.3) 26 (4.5) 21 (4.7) 9 (4.3) 14 (5.5)
Constipation 28 (3.3) 23 (3.9) 21 (4.7) 16 (7.6) 15 (5.9)
Vomiting 15 (1.7) 16 (2.7) 23 (5.1) 13 (6.2) 16 (6.3)
TEAEs leading to discontinuation Z2 patients in any treatment arm, n (%)
Nausea 3 (0.3) 9 (1.5) 7 (1.6) 5 (2.4) 11 (4.3)
Vomiting 3 (0.3) 0 4 (0.9) 2 (1.0) 0
Headache 2 (0.2) 1 (0.2) 1 (0.2) 2 (1.0) 2 (0.8)
Insomnia 1 (0.1) 3 (0.5) 1 (0.2) 1 (0.5) 0
Anxiety 3 (0.3) 1 (0.2) 1 (0.2) 2 (1.0) 0
Depression 5 (0.6) 1 (0.2) 3 (0.7) 0 0
Dizziness 2 (0.2) 1 (0.2) 2 (0.4) 1 (0.5) 0
Abdominal pain
upper
3 (0.3) 0 1 (0.2) 1 (0.5) 1 (0.4)
Constipation 0 1 (0.2) 0 0 2 (0.8)
Irritability 2 (0.2) 0 1 (0.2) 0 1 (0.4)
Suicidal ideation 4 (0.5) 0 1 (0.2) 0 1 (0.4)
Suicide attempt 0 1 (0.2) 2 (0.4) 0 1 (0.4)
Agitation 2 (0.2) 1 (0.2) 0 0 0
Dyspepsia 2 (0.2) 0 0 0 0
Crying 2 (0.2) 0 0 0 0
N represents all randomized patients who took at least 1 dose of study drug.
Adverse events occurring on or after the ﬁrst dose and within 30 days post dosing
are included.
Studies included in the safety analysis: NCT00839423, NCT00635219,
NCT00735709, NCT01140906, NCT01153009, NCT01163266, NCT01255787,
NCT00672958, NCT00672620, NCT01179516, and NCT00811252 (elderly).
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Z20 reached statistical signiﬁcance for vortioxetine 5 mg/day
(Po0.001) and 10 mg/day (Po0.001), with 20 mg/day almost
reaching the 0.05 signiﬁcance level (P¼0.054) (Fig. 5). These re-
sults also demonstrated the dose-dependent relationship of vor-
tioxetine 5, 10, and 20 mg/day. The meta-analysis of non-US stu-
dies demonstrated a possible dose-response trend with vortiox-
etine 5 mg/day (Po0.001), 10 mg/day (Po0.001), and 15 mg/day
(Po0.001), but not for vortioxetine 20 mg/day (P¼0.115).
The CGI-S meta-analysis in patients with MDD and high levels
of anxiety symptoms yielded very similar results in both the total
subgroup and the non-US subgroup. In all patients with baseline
HAM-A total score Z20, the difference from placebo was statis-
tically signiﬁcant for vortioxetine 5 mg/day (P¼0.003), 10 mg/day
(Po0.001), and 20 mg/day (P¼0.003), but not for vortioxetine
15 mg/day (P¼0.609). In the non-US subgroup, a statistically sig-
niﬁcant difference from placebo in change from baseline on CGI-S
score was achieved by all vortioxetine doses (5 mg/day, P¼0.014;
10 mg/day, Po0.001; 15 mg/day, Po0.001; 20 mg/day, P¼0.013)
(Supplemental Fig. 2).
3.3. Safety and tolerability
The safety proﬁle of vortioxetine 5–20 mg/day in patients with
high levels of anxiety symptoms is shown in Table 2. Rates of the
most frequently reported (Z5% in any treatment arm) TEAEs (i.e.,
nausea, headache, dizziness, dry mouth, diarrhea, nasopharyngitis,
constipation, and vomiting) were similar to those observed in the
overall MDD population, with no difference in the incidence or
prevalence of TEAEs, including anxiogenic effects, observed in the
ﬁrst 2 weeks of treatment when compared to the overall safety
results (Takeda Pharmaceuticals America Inc., 2016). Nausea was
the only TEAE with an overall incidence that was Z2 times higher
in the vortioxetine treatment arms than in the placebo arm, which
followed a dose-related trend. Discontinuations due to TEAEs were
slightly more frequent with vortioxetine and showed a dose-de-
pendent increase. Nausea accounted for the largest percentage of
discontinuations due to TEAEs and showed a dose-related pattern;
nausea resulted in the discontinuation of 0.3% of the placebo
group and 1.5%, 1.6%, 2.4%, and 4.3% of the vortioxetine 5, 10, 15,
and 20 mg/day groups, respectively. The rates of serious TEAEs and
discontinuations due to serious TEAEs were similar to placebo in
all vortioxetine treatment groups. The safety proﬁle of vortioxetine
5–20 mg/day in patients with high levels of anxiety symptoms was
similar to the overall MDD population (Takeda Pharmaceuticals
America Inc., 2016).
Similar to the safety analysis of vortioxetine in patients with
depressive disorders (Baldwin et al., 2016), there was no evidence
to suggest that initiation of vortioxetine is associated with anxio-
genic effects in this subgroup of MDD patients with high anxiety
levels, as assessed by the emergence of anxiety-related adverse
events (e.g., irritability, fatigue, jitteriness, malaise, restlessness,
tension, anxiety, and insomnia) at any study visit during the
duration of the clinical trials (data not shown).4. Discussion
High levels of anxiety symptoms are seen in approximately half
of all individuals with MDD (Kessler et al., 2015; Schuch et al.,
2014). The need to identify more effective and better-tolerated
therapies for this subgroup of patients is driven by evidence that
they are less responsive to and less tolerant of antidepressant
therapies than are individuals with non-anxious depression (Fava
et al., 2008; Ionescu et al., 2014). Meta-analyses of data from 10
short-term, randomized, placebo-controlled vortioxetine clinicaltrials were conducted to determine whether vortioxetine may be a
treatment option for depressed patients with high levels of anxi-
ety. Vortioxetine (5–20 mg/day) demonstrated effective anti-
depressant activity in patients with MDD and high levels of an-
xiety symptoms at baseline (HAM-A total score Z20). For vor-
tioxetine 10 mg/day, the recommended starting dose, the LS mean
difference from placebo in change from baseline in MADRS total
score was 3.59 points (SES 0.40), which exceeds the “clinically
meaningful” threshold of a two-point difference from placebo in
change from baseline to study endpoint in MADRS total score
(Montgomery and Moller, 2009). Among patients with more se-
vere anxiety symptoms (baseline HAM-A total score Z25) en-
rolled in these trials, patients receiving vortioxetine 10 mg/day
had an LS mean difference from placebo in change from baseline
in MADRS total score of 3.82, which translated to a standardized
effect size of 0.40. However, in this subgroup, the standardized
effect sizes were smaller in the 5-, 15-, and 20-mg/day dosing
groups. This may be due to insufﬁcient sample sizes, particularly in
the vortioxetine 15 mg/day (n¼70) and 20 mg/day dose (n¼85)
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xiety symptoms (baseline HAM-A total score o20) identiﬁed a
similar dose-dependent effect to that seen in the overall study
population, as well as those patients with high anxiety symptoms
at baseline (Takeda Pharmaceuticals America Inc., 2016). The
standardized effect sizes for change from baseline in MADRS total
scores to study end in the population of MDD patients with high-
level anxiety symptoms were similar to those observed in the
overall MDD population (Baldwin et al., 2014b; Thase et al., 2016),
where standard effect sizes were vortioxetine 5 mg; 0.22; 10 mg,
0.32; 15 mg, 0.20; and 20 mg, 0.41. The number needed to
treat scores were also similar in the population of patients with
high baseline HAM-A scores to the overall MDD population, which
were previously reported as vortioxetine 5 mg; 15; 10 mg, 16;
15 mg, 21; and 20 mg, 12. (Thase et al., 2016) Similar rates of re-
sponse and remission were also identiﬁed. (Baldwin et al., 2014b;
Thase et al., 2016).
The efﬁcacy of vortioxetine in reducing anxiety symptoms in
the overall MDD population and in the MDD subgroup with high
levels of anxiety at baseline was investigated. Standardized effect
sizes for vortioxetine 10 mg/day were 0.29 in the overall MDD
population and 0.31 in the subgroup with high levels of anxiety,
suggesting these groups experience similar anxiolytic efﬁcacy.
Consistent with studies of other therapies, the effects in the high
anxiety subgroup took longer to separate from placebo (Altamura
et al., 2004; Davidson et al., 2002; Fava et al., 2008). In the overall
MDD group, the vortioxetine 10 and 20 mg/day doses separated
from placebo at the ﬁrst on-treatment study visit, whereas it took
until the second on-treatment study visit to see a signiﬁcant im-
provement in the patients with high levels of anxiety symptoms.
When the effect of vortioxetine was assessed for anxious mood,
the symptoms captured by the psychic anxiety subscale and the
somatic anxiety subscale, the greatest improvement was observed
in the psychic anxiety subscale in these short-term studies. There
was improvement in the anxious mood subscale and, to a lesser
degree, in the somatic anxiety subscale as well. This result is si-
milar to that seen on MADRS Item 3 (inner tension), where there
was a consistent, dose-related effect in favor of vortioxetine. This
item refers to feelings of ill-deﬁned discomfort, edginess, inner
turmoil, or mental tension mounting to either panic, dread, or
anguish (Montgomery and Asberg, 1979) and has been used in
other studies of MDD to assess anxiolytic effects of antidepressant
treatment (Bandelow et al., 2007; Gorman et al., 2002; Thase et al.,
2014).
The CGI-I and CGI-S scores supported the ﬁndings that vor-
tioxetine is efﬁcacious in the often difﬁcult-to-treat MDD popu-
lation with high levels of anxiety symptoms.
With the exception of vortioxetine 15 mg/day, outcomes
showed a dose-dependent trend. The inconsistencies in results for
vortioxetine 15 mg/day may be attributed, at least in part, to
having had the smallest sample size because the dose was only
utilized in 3 clinical trials (2 of which were based in the US). As a
result, this dose was associated with substantially wider con-
ﬁdence intervals compared with the other doses.
When meta-analyses were performed using data from the
5 non-US studies, efﬁcacy outcomes were more robust and con-
sistent across dosing groups. The reasons for this difference are not
completely understood and are discussed elsewhere (Thase et al.,
2016). Other studies have reported important differences between
the US and other countries with regard to patient characteristics,
diagnostic and clinical practices, and the conduct of clinical trials
(Chang et al., 2008; Dunlop et al., 2012; Khin et al., 2011; Niklson
and Reimitz, 2001; Vieta et al., 2011; Welten et al., 2015).
In the study that included patients aged Z65 years exclusively,
vortioxetine 5 mg/day was efﬁcacious in treating late-life depres-
sion in both the overall population (Katona et al., 2012), as well asin the subgroup of individuals with high levels of anxiety symp-
toms at baseline.
Finally, comparison of TEAEs found that the safety proﬁle of
vortioxetine was similar in the subgroup of patients with MDD and
high levels of anxiety symptoms and in the total population of
patients with MDD. Initiation of vortioxetine had no apparent
anxiogenic effects in MDD patients with a high level of anxiety
symptoms.5. Limitations
This study conducted meta-analyses of study-level data from
10 randomized, placebo-controlled trials at differering study cen-
tres, which are inherently heterogeneous. No direct conclusions
can be drawn about the efﬁcacy of vortioxetine in the group with
baseline HAM-A total scores Z20 relative to the group with
baseline HAM-A total score o20 or to the overall MDD popula-
tion. Limited conclusions can also be made regarding the 15 mg/
day dose, as only 3 of the 11 total studies included in this meta-
analysis included this dose as an active treatment arm.
Characterization of “anxious depression” is confounded by the
lack of a consistent deﬁnition across trials. Deﬁnitions range from
MDD with comorbid anxiety disorders to MDD with one of several
measures of anxiety symptoms. A commonly used threshold is the
HAM-D anxiety/somatization subscale score Z7 (Ionescu et al.,
2014; Matza et al., 2010). This analysis used a HAM-A total score
cutoff of 20 (as predeﬁned in the individual study protocols) to
stratify patients by baseline anxiety symptom severity (high levels
versus low levels), which has been used in other studies of MDD
(Bandelow et al., 2014; Boulenger et al., 2010; Seo et al., 2011; Seo
et al., 2014; Thase et al., 2012). The HAM-A total score cutoff of 20
has also been used as an entry criterion for studies of patients with
GAD (Baldwin et al., 2006; Gommoll et al., 2015; Rickels et al.,
2005). This cutoff was predeﬁned in the individual study protocols
with the idea that using a scale designed to assess anxiety
symptoms should be more sensitive than a subscore on a de-
pression scale. This analysis did not relate ﬁndings based on HAM-
A total score Z20 to those using HAM-D anxiety/somatization
score Z7, which limits inferential comparison with other studies.
Moreover, because individuals with any current psychiatric dis-
order other than MDD were excluded from the studies included
here, the results of these meta-analyses cannot be generalized to
patients with comorbid MDD and anxiety disorders. However, in
the STAR*D population, patients with anxious depression (HAM-D
anxiety/somatization score Z7) met the criteria for anxiety dis-
orders without having been diagnosed (Fava et al., 2008).6. Conclusions
This meta-analysis of data from more than 2800 vortioxetine-
treated patients in 10 randomized, placebo-controlled, short-term
adult MDD studies indicates that in almost 1400 depressed pa-
tients with a high level of anxiety (HAM-A total score Z20),
vortioxetine (across daily doses of 5–20 mg) is an efﬁcacious
treatment choice for depressed patients with anxious symptoms,
with increasing efﬁcacy versus placebo with increasing dose. The
broad clinical efﬁcacy proﬁle of vortioxetine was demonstrated on
multiple analyses of the MADRS total score, HAM-A total score,
CGI-I score, and CGI-S score, as well as on various individual item
analyses. Vortioxetine was generally safe and well tolerated in
patients with MDD and high levels of anxiety symptoms.
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